Clinical trials · California
Hemophilia A clinical trials in California
We’re tracking 20 recruiting hemophilia a studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06349473RecruitingPhase 1
Study of SR604 in healthy people and those with bleeding disorders
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
Glendale, CaliforniaAges 18–60 - NCT04647227RecruitingPhase 4
SEVENFACT® to reduce bleeding in hemophilia with inhibitors
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Los Angeles, CaliforniaAges 12–100 - NCT05568719RecruitingPhase 3
Testing gene therapy for hemophilia A or B
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
Rancho Cordova, CaliforniaAges 18 years+ - NCT06003387RecruitingPhase 3
Gene therapy for hemophilia B with AAV5 antibodies
This trial tests a gene therapy called CSL222 for adults with hemophilia B who have antibodies against the AAV5 virus used to deliver the therapy. It aims to see if the treatment is safe and effective even when these antibodies are present.
San Diego, CaliforniaAges 18 years+ - NCT07080905RecruitingPhase 3
Gene therapy for teens with severe hemophilia B
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
Orange, CaliforniaAges 11.5 years–17.2 years - NCT07416604RecruitingPhase 3
Study of NXT007 vs emicizumab for hemophilia A
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Orange, CaliforniaAges 12 years+ - NCT06379789RecruitingPhase 1/Phase 2
Gene therapy for severe hemophilia B
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
Los Angeles, CaliforniaAges 2 years+ - NCT07226206RecruitingPhase 1/Phase 2
Gene therapy for adults with severe hemophilia A
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Orange, CaliforniaAges 18 years+ - NCT04131036Recruiting
Compare emicizumab and factor VIII for joint and bone health
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
San Diego, CaliforniaAges 16 years+ - NCT06145373RecruitingPhase 4
Fitusiran for preventing bleeds in severe hemophilia A
This study tests a new medicine called fitusiran to help prevent bleeding episodes in people with severe hemophilia A who are already receiving emicizumab. It may offer an additional treatment option for those with or without inhibitors.
Los Angeles, CaliforniaAges 12 years+ - NCT06703606RecruitingPhase 1
Switching from Emicizumab to Marstacimab for Severe Hemophilia A
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
Los Angeles, CaliforniaAges 12–74 - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for severe or moderate hemophilia A
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Sacramento, CaliforniaAges 2–59 - NCT05022459Recruiting
Prevent bleeding in kids with Hemophilia A who play sports
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
San Diego, CaliforniaAges 6–19 - NCT07285460RecruitingPhase 3
Fitusiran for young boys with hemophilia A or B
This trial tests if fitusiran, given as a shot, can help prevent bleeding in boys ages 1 to 12 with severe hemophilia (factor VIII under 1% or factor IX at 2% or lower). It includes boys with or without inhibitors and aims to understand safety and how well it works.
Orange, CaliforniaAges 1–11 - NCT05962398Enrolling by invitation
Follow-up study for men previously treated with CSL222
This study checks long-term safety and outcomes in men with hemophilia B who previously received CSL222. It may help your care team better understand how well the treatment lasts over many years.
Los Angeles, CaliforniaAges 18 years+ - NCT05768386Enrolling by invitation
Long-term follow-up for severe hemophilia A after BMN 270 study
This study checks how people with severe hemophilia A are doing over time after joining a previous BioMarin study of BMN 270. It helps researchers understand long-term safety and outcomes and may support your ongoing care plan.
Sacramento, CaliforniaAges 18 years+ - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Los Angeles, CaliforniaAges birth–20 years - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Los Angeles, CaliforniaAges Any age - NCT05500807RecruitingPhase 1
Emicizumab study for severe von Willebrand disease or overlap disorder
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
Redwood City, CaliforniaAges birth–90 years - NCT06941870RecruitingPhase 4
Efanesoctocog Alfa Preventative Treatment for Hemophilia A with Joint Thickening
This study tests a new preventive treatment (efanesoctocog alfa) for people with hemophilia A who have joint lining thickening. The goal is to see if it helps protect joints.
Los Angeles, CaliforniaAges 12 years+
Hemophilia A trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting hemophilia a studies listed above.
- Children's Hospital Los Angeles · 5 studies
- Orthopaedic Institute for Children · 5 studies
- UC Davis Health · 4 studies
- University of California, Davis Medical Center · 4 studies
- University of California, San Francisco · 4 studies
- Center for Inherited Blood Disorders · 3 studies
- Hemophilia and Thrombosis Treatment Center at UC San Diego Health · 2 studies
- Orthopaedic Hemophilia Treatment Center · 2 studies
What taking part in a hemophilia a study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hemophilia A trials in other states
Common questions
- Are there hemophilia a clinical trials in California?
- Yes. We're currently tracking 20 recruiting hemophilia a studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hemophilia a study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hemophilia a studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.